Kitamura Y, Kanaya N, Moleirinho S, Du W, Reinshagen C, Attia N, et al. Anti-EGFR VHH-armed death receptor ligand-engineered allogeneic stem cells have therapeutic efficacy in diverse brain metastatic breast cancers. Sci Adv. 2021;7: pubmed publisher

Seitz C, Schroeder S, Knopf P, Krahl A, Hau J, Schleicher S, et al. GD2-targeted chimeric antigen receptor T cells prevent metastasis formation by elimination of breast cancer stem-like cells. Oncoimmunology. 2020;9:1683345 pubmed publisher

Edinger N, Lebendiker M, Klein S, Zigler M, Langut Y, Levitzki A. Targeting polyIC to EGFR over-expressing cells using a dsRNA binding protein domain tethered to EGF. PLoS ONE. 2016;11:e0162321 pubmed publisher

Jacquot P, Mu xf1 oz Garcia J, Fleury M, Cochonneau D, Gaussin R, Enouf E, et al. Engineering of a Bispecific Nanofitin with Immune Checkpoint Inhibitory Activity Conditioned by the Cross-Arm Binding to EGFR and PDL1. Biomolecules. 2023;13: pubmed publisher

Jo D, Kaczmarek S, Shin O, Wang L, Cowan J, McComb S, et al. Simultaneous engineering of natural killer cells for CAR transgenesis and CRISPR-Cas9 knockout using retroviral particles. Mol Ther Methods Clin Dev. 2023;29:173-184 pubmed publisher

An L, Wang Y, Wu G, Wang Z, Shi Z, Liu C, et al. Defining the sensitivity landscape of EGFR variants to tyrosine kinase inhibitors. Transl Res. 2023;255:14-25 pubmed publisher

Quijano Rubio A, Bhuiyan A, Yang H, Leung I, Bello E, Ali L, et al. A split, conditionally active mimetic of IL-2 reduces the toxicity of systemic cytokine therapy. Nat Biotechnol. 2023;41:532-540 pubmed publisher

Cheng C, Cui H, Liu H, Wu Y, Ding N, Weng Y, et al. Role of Epidermal Growth Factor Receptor-Specific CAR-T Cells in the Suppression of Esophageal Squamous Cell Carcinoma. Cancers (Basel). 2022;14: pubmed publisher

Wang J, Lee W, Fang C, Hsu H, Chen B, Liu H. Human Papillomavirus Oncoproteins Confer Sensitivity to Cisplatin by Interfering with Epidermal Growth Factor Receptor Nuclear Trafficking Related to More Favorable Clinical Survival Outcomes in Non-Small Cell Lung Cancer. Cancers (Basel). 2022;14: pubmed publisher

Carnevale J, Shifrut E, Kale N, Nyberg W, Blaeschke F, Chen Y, et al. RASA2 ablation in T cells boosts antigen sensitivity and long-term function. Nature. 2022;609:174-182 pubmed publisher

Jayasinghe M, Pirisinu M, Yang Y, Peng B, Pham T, Lee C, et al. Surface-engineered extracellular vesicles for targeted delivery of therapeutic RNAs and peptides for cancer therapy. Theranostics. 2022;12:3288-3315 pubmed publisher

Lu T, Ma R, Dong W, Teng K, Kollath D, Li Z, et al. Off-the-shelf CAR natural killer cells secreting IL-15 target spike in treating COVID-19. Nat Commun. 2022;13:2576 pubmed publisher

Brohl A, Sindiri S, Wei J, Milewski D, Chou H, Song Y, et al. Immuno-transcriptomic profiling of extracranial pediatric solid malignancies. Cell Rep. 2021;37:110047 pubmed publisher

Li G, Guo J, Zheng Y, Ding W, Han Z, Qin L, et al. CXCR5 guides migration and tumor eradication of anti-EGFR chimeric antigen receptor T cells. Mol Ther Oncolytics. 2021;22:507-517 pubmed publisher

Okada R, Furusawa A, Vermeer D, Inagaki F, Wakiyama H, Kato T, et al. Near-infrared photoimmunotherapy targeting human-EGFR in a mouse tumor model simulating current and future clinical trials. EBioMedicine. 2021;67:103345 pubmed publisher

Fischer A, Wolf I, Fuchs H, Masilamani A, Wolf P. Pseudomonas Exotoxin A Based Toxins Targeting Epidermal Growth Factor Receptor for the Treatment of Prostate Cancer. Toxins (Basel). 2020;12: pubmed publisher

Sreevalsan S, Döring M, Paszkowski Rogacz M, Brux M, Blanck C, Meyer M, et al. MLLT6 maintains PD-L1 expression and mediates tumor immune resistance. EMBO Rep. 2020;:e50155 pubmed publisher

Leelatian N, Sinnaeve J, Mistry A, Barone S, Brockman A, Diggins K, et al. Unsupervised machine learning reveals risk stratifying glioblastoma tumor cells. elife. 2020;9: pubmed publisher

Ahn S, Li J, Sun C, Gao K, Hirabayashi K, Li H, et al. Cancer Immunotherapy with T Cells Carrying Bispecific Receptors That Mimic Antibodies. Cancer Immunol Res. 2019;7:773-783 pubmed publisher

Aldeghaither D, Zahavi D, Murray J, Fertig E, Graham G, Zhang Y, et al. A Mechanism of Resistance to Antibody-Targeted Immune Attack. Cancer Immunol Res. 2019;7:230-243 pubmed publisher

Wing A, Fajardo C, Posey A, Shaw C, Da T, Young R, et al. Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus-Driven Production of a Bispecific T-cell Engager. Cancer Immunol Res. 2018;6:605-616 pubmed publisher

Han X, Cinay G, Zhao Y, Guo Y, Zhang X, Wang P. Adnectin-Based Design of Chimeric Antigen Receptor for T Cell Engineering. Mol Ther. 2017;25:2466-2476 pubmed publisher

Halim L, Romano M, McGregor R, Correa I, Pavlidis P, Grageda N, et al. An Atlas of Human Regulatory T Helper-like Cells Reveals Features of Th2-like Tregs that Support a Tumorigenic Environment. Cell Rep. 2017;20:757-770 pubmed publisher

Bak R, Porteus M. CRISPR-Mediated Integration of Large Gene Cassettes Using AAV Donor Vectors. Cell Rep. 2017;20:750-756 pubmed publisher

Jarantow S, Bushey B, Pardinas J, Boakye K, Lacy E, Sanders R, et al. Impact of Cell-surface Antigen Expression on Target Engagement and Function of an Epidermal Growth Factor Receptor × c-MET Bispecific Antibody. J Biol Chem. 2015;290:24689-704 pubmed publisher

Wang Y, Zhou J, Qiu L, Wang X, Chen L, Liu T, et al. Cisplatin-alginate conjugate liposomes for targeted delivery to EGFR-positive ovarian cancer cells. Biomaterials. 2014;35:4297-309 pubmed publisher

Grass G, Tolliver L, Bratoeva M, Toole B. CD147, CD44, and the epidermal growth factor receptor (EGFR) signaling pathway cooperate to regulate breast epithelial cell invasiveness. J Biol Chem. 2013;288:26089-104 pubmed publisher